Views & Analysis Insight, market monitoring and assessing whether a brand pla... This article is the last in a series of three from Osprey Health Consulting.
News FDA greenlights Regeneron drug for rare bone disease Regeneron's Pasatru will be the second FDA-approved treatment for fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
